A probable carcinogen has been detected in the heartburn drug Zantac and its generic versions, prompting the recall of several versions of blood pressure-lowering pills.

FDA finds small amounts of probable carcinogen in Zantac and other heartburn drugs

The FDA tested ranitidine heartburn medications and found small amounts of a probable carcinogen. The agency has not recommended the drugs be recalled


USA News